Non-alcoholic Steatohepatitis Therapeutics Market to Grow at a CAGR of 13.6% during the 2022 to 2031 Forecast Period: TMR Study
July 07, 2023 07:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis therapeutics market stood at US$ 10.1 billion in 2021 and the global non-alcoholic...
Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight
May 23, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 23, 2023 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight Nonalcoholic steatohepatitis...
Nonalcoholic Steatohepatitis Therapeutics Market Expands with Rising Cases of Obesity and Diabetes, States TMR Report
June 21, 2022 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 21, 2022 (GLOBE NEWSWIRE) -- The global nonalcoholic steatohepatitis therapeutics market is estimated to register growth at a CAGR of 13.6% during the...
Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
January 13, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020 NASH Drug Pipeline Shows Promise as 95+ companies are working for...
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT
January 01, 2021 19:15 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
July 30, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
May 04, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Taconic Biosciences Releases First Off-the-Shelf NASH Animal Model
July 29, 2019 09:00 ET
|
Taconic Biosciences
RENSSELAER, N.Y., July 29, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the first commercially available...
Endonovo Therapeutics Provides Update on Liver Study
October 22, 2018 10:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies,...
ConSynance Presents CSTI-100 Data at NASH Conference
September 27, 2018 09:00 ET
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., Sept. 27, 2018 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. announced today that Peter Guzzo, Ph.D., CEO, gave an oral presentation regarding the company's Phase I...